Mount Sinai Network of Excellence in Neuroscience Clinical Trials

西奈山神经科学临床试验卓越网络

• 批准号: 10438736
• 负责人: Nathalie Jette
• 金额: $ 33.9万
• 依托单位: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-07-15 至 2024-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10438736
• 关键词: Adult; African American population; Agreement; Authorship; Biological Markers; Capital; Caring; Child; Childhood; Chronic Fatigue Syndrome; Clinical; Clinical Research; Clinical Trials; Clinical Trials Design; Collaborations; Contracts; Data Collection; Degree program; Department chair; Development; Development Plans; Discipline; Drug resistance; Effectiveness; Ensure; Ethnic group; Faculty; Fellowship; Fund Raising; Future; Health system; Hispanic Populations; Infrastructure; Institution; Institutional Review Boards; International; Interview; Knowledge; Lead; Leadership; Letters; Mentors; Minority Groups; Mission; Movement Disorders; Multiple Sclerosis; Municipal Hospitals; Neurologic; Neurologist; Neurology; Neuromuscular Diseases; Neuropsychology; Neurosciences; Neurosciences Research; New York City; Ophthalmology; Outcome; Outcomes Research; Participant; Patients; Pediatric Neurology; Persons; Population; Population Heterogeneity; Positioning Attribute; Protocols documentation; Publications; Publishing; Quality of life; Records; Research; Research Infrastructure; Research Personnel; Residencies; Resources; Scholarship; Schools; Seasons; Services; Site; Societies; South Asian; Spinal cord injury; Standardization; Testing; Therapy trial; Time; Training; Training Programs; Translating; Underinsured; Visit; Woman; career; certificate program; childhood epilepsy; data quality; ethnic diversity; evidence base; experience; faculty research; graduate medical education; health outcome disparity; improved; investigator-initiated trial; medical schools; multi-ethnic; nervous system disorder; neuro-oncology; neuroAIDS; neurological rehabilitation; neuropathology; novel therapeutics; outreach; patient population; professor; programs; protocol violation; racial diversity; recruit; research study; skills; socioeconomics; training opportunity; translational neuroscience

Well-designed clinical trials are necessary in order to effectively test the best evidence-based, biomarker informed when possible, therapies to persons living with neurological conditions. However, these can be challenging to implement when resources are fragmented and when a condition is so rare that single center recruitment is not possible. The Icahn School of Medicine at Mount Sinai (ISMMS) NeuroNEXT team supports the notion that in order to translate the best neurological evidence, it is necessary to minimize duplication of efforts by increasing collaboration with stakeholders across multiple conditions, disciplines and centers. Rationale: The Department of Neurology and collaborators at the ISMMS have the trialists, related expertise (e.g. neuroradiology, neuro-psychology, neurorehabilitation, neuropathology, biomarker and health outcomes/disparities research), clinical trials research infrastructure, large and diverse population and local and institutional leadership support to be a new, successful, and actively contributing NeuroNEXT site. Aims: We are committed to collaborating in conducting at least 4 trials of therapies (as required by NeuroNEXT) that have the potential to improve the lives of persons with neurological conditions and to utilize a central IRB and standardized master contract agreement. With access to a large population of highly diverse socio-economic strata across multiple boroughs of New York City and beyond, Mount Sinai NeuroNEXT team will lead and support trials across a broad range of conditions, in both pediatric and adult populations, and will train and mentor at least 2-3 junior investigators to become future clinical trials leaders in neurology. We will share knowledge (bi-directionally) about effective practices in recruitment, retention and outreach with other sites around the US and will actively engage in network workgroups and committees, to strengthen the impact of the research. Expected outcomes: Ultimately, Mount Sinai NeuroNEXT, committed to participate collaboratively and effectively in testing of the new therapies, will contribute to trials aimed at improving quality of life and outcomes in children and adults afflicted by a neurological condition. Mount Sinai NeuroNEXT will also contribute to the training of junior investigators who will become future clinical trialists.

必须进行精心设计的临床试验，以便在可能的情况下对患有神经系统疾病的人进行有效测试最佳的基于证据的生物标志物。但是，当资源分散时，这些情况可能具有挑战性，并且当条件如此罕见以至于无法进行单一中心招聘时。西奈山（ISMMS）神经网络小组的伊坎医学院支持这样的观念：为了翻译最佳的神经学证据，有必要通过增加与利益相关者在多种条件，纪律和中心之间与利益相关者的协作来最大程度地减少重复的努力。 理由：ISMM的神经病学和合作者系具有试验者，相关的专业知识（例如，神经放射学，神经心理学，神经康复，神经病理学，神经病理学，生物标志物以及健康成果/差异研究），临床试验研究基础结构，大型和多样性的人群和社会领导地位，并成为新的领导力和机构的领导力，并成为一名新的机构。 目的：我们致力于合作进行至少4项疗法试验（根据Neuronext的要求），这些试验有可能改善具有神经系统条件的人的生活并利用中央IRB和标准化的总合同协议。随着纽约市及其他多个行政区的大量社会经济地层的大量人口，西奈山Neuronext团队将在儿科和成人人口中领导和支持广泛条件的试验，并将培训和导师至少培训和导师至少2-3名初级研究员，以成为Neurology的未来临床试验者。我们将（双向）（双向）与美国其他站点的招聘，保留和推广实践分享知识，并将积极参与网络工作组和委员会，以增强研究的影响。 预期的结果：最终，西奈山神经网站（Mount Sinai Neuronext）致力于合作有效地测试新疗法，将有助于改善患有神经系统疾病的儿童和成人的生活质量和成人的试验。西奈山Neuronext还将为将成为未来临床试验者的初级研究人员的培训做出贡献。

项目成果

Nonelective hospital admissions, discharge disposition, and health services utilization in epilepsy patients: A population-based study.

癫痫患者的非选择性入院、出院处理和卫生服务利用：一项基于人群的研究。

• DOI: 10.1111/epi.16642
• 发表时间: 2020
• 期刊: Epilepsia
• 影响因子: 5.6
• 作者: Kwon,Churl-Su;Wong,Bonnie;Agarwal,Parul;Lin,Jung-Yi;Mazumdar,Madhu;Dhamoon,Mandip;Jetté,Nathalie
• 通讯作者: Jetté,Nathalie

Risk of readmission for injury in patients with epilepsy in the United States - A population-based study.

美国癫痫患者因受伤再次入院的风险 - 一项基于人群的研究。

• DOI: 10.1016/j.yebeh.2019.106651
• 发表时间: 2020
• 期刊: Epilepsy & behavior : E&B
• 作者: Kwon,Churl-Su;Agrawal,Parul;Goldstein,Jonathan;Dhamoon,Mandip;Mazumdar,Madhu;Jetté,Nathalie
• 通讯作者: Jetté,Nathalie

Exacerbation of hepatic cirrhosis may trigger admission for epilepsy and status epilepticus.

肝硬化恶化可能会引发癫痫和癫痫持续状态入院。

• DOI: 10.1111/epi.16437
• 发表时间: 2020
• 期刊: Epilepsia
• 影响因子: 5.6
• 作者: Gursky,JonathanM;Rossi,KyleC;Jetté,Nathalie;Dhamoon,MandipS
• 通讯作者: Dhamoon,MandipS

Depression readmission risk is elevated in multiple sclerosis compared to other chronic illnesses.

与其他慢性疾病相比，多发性硬化症患者的抑郁症再入院风险较高。

• DOI: 10.1177/13524585211051316
• 发表时间: 2022
• 期刊: Multiple sclerosis (Houndmills, Basingstoke, England)
• 作者: Schorr,EmilyM;Kurz,Daniel;Rossi,KyleC;Zhang,Margaret;Yeshokumar,AnushaK;Jette,Nathalie;Dhamoon,MandipS
• 通讯作者: Dhamoon,MandipS